Industry News
Biotechnology Industry News

JPM22, Day 1: Bayer strikes a Mammoth deal, no Sunday buyouts, Pfizer delves deeper in gene editing and more
JPM22, Day 1: Bayer strikes a Mammoth deal, no Sunday buyouts, Pfizer delves deeper in gene editing and more badams Mon, 01/10/2022 - 04:25
JPM 2022: Bayer taps CRISPR science from Doudna’s lab in $1B biobucks Mammoth gene therapy deal
JPM 2022: Bayer taps CRISPR science from Doudna's lab in $1B biobucks Mammoth gene therapy deal aliu Sat, 01/08/2022 - 06:42
JPM 2022: Pfizer re-ups gene editing interest with $300M Beam pact, $1.35B in biobucks
JPM 2022: Pfizer re-ups gene editing interest with $300M Beam pact, $1.35B in biobucks aarmstrong Fri, 01/07/2022 - 12:50
Merck leans into AI with $610M in biobucks for Absci drug discovery pact
Merck leans into AI with $610M in biobucks for Absci drug discovery pact aarmstrong Fri, 01/07/2022 - 10:38
Atea sticks it out with failed COVID-19 antiviral but also raids Merck’s store room for hepatitis C drug
Atea sticks it out with failed COVID-19 antiviral but also raids Merck's store room for hepatitis C drug aarmstrong Fri, 01/07/2022 - 10:02
Cytokinetics finds worldwide partner in Royalty Pharma for heart failure drug, snags up to $450M to extend runway
Cytokinetics finds worldwide partner in Royalty Pharma for heart failure drug, snags up to $450M to extend runway aarmstrong Fri, 01/07/2022 - 09:11
AstraZeneca picks up new weapon in rare disease fight with Alnylam and Pfizer, paying $30M for rights to an early-phase asset
AstraZeneca picks up new weapon in rare disease fight with Alnylam and Pfizer, paying $30M for rights to an early-phase asset ntaylor Fri, 01/07/2022 - 07:35
Chutes & Ladders—Maraganore’s post-Alnylam ambitions take flight
Chutes & Ladders—Maraganore's post-Alnylam ambitions take flight fkansteiner Thu, 01/06/2022 - 14:53
Aligos says stop right now to lead hep B med after fruitless phase 1 data
Aligos says stop right now to lead hep B med after fruitless phase 1 data aarmstrong Thu, 01/06/2022 - 14:49
Sanofi makes AI play, putting up $100M and billions in biobucks to form broad deal with Exscientia
Sanofi makes AI play, putting up $100M and billions in biobucks to form broad deal with Exscientia ntaylor Thu, 01/06/2022 - 11:51
Amgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugs
Amgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugs aarmstrong Thu, 01/06/2022 - 09:19
Sanofi tears up Sangamo cell therapy deal in pivot to off-the-shelf approaches
Sanofi tears up Sangamo cell therapy deal in pivot to off-the-shelf approaches ntaylor Thu, 01/06/2022 - 08:08
Novartis taps Alnylam for ambitious push to fix liver function
Novartis taps Alnylam for ambitious push to fix liver function ntaylor Thu, 01/06/2022 - 07:29
Eikon Therapeutics snares $500M series B, pinning constellation of biotech stars to its upper ranks
Eikon Therapeutics snares $500M series B, pinning constellation of biotech stars to its upper ranks fkansteiner Wed, 01/05/2022 - 15:18
Eli Lilly taps Entos’ delivery tech in $50M-plus nucleic acid pact
Eli Lilly taps Entos' delivery tech in $50M-plus nucleic acid pact fkansteiner Wed, 01/05/2022 - 13:31
Annexon shares dip 30% as patient dropouts dog midphase Huntington’s trial
Annexon shares dip 30% as patient dropouts dog midphase Huntington's trial aarmstrong Wed, 01/05/2022 - 12:52
Ultragenyx granted go-ahead to up doses for Angelman antisense therapy that stalled after safety issues
Ultragenyx granted go-ahead to up doses for Angelman antisense therapy that stalled after safety issues aarmstrong Wed, 01/05/2022 - 11:15
VCs plow $115M into next-gen genetic medicine startup SalioGen, teeing up work on eye and liver diseases
VCs plow $115M into next-gen genetic medicine startup SalioGen, teeing up work on eye and liver diseases ntaylor Wed, 01/05/2022 - 06:05
Intellia bags option on autoimmune CAR-T prospect, handing Kyverna rights to use CRISPR tech to create off-the-shelf cell therapy
Intellia bags option on autoimmune CAR-T prospect, handing Kyverna rights to use CRISPR tech to create off-the-shelf cell therapy ntaylor Wed, 01/05/2022 - 05:56
Exelixis nabs Merck veteran as chief medical officer on quest to expand its R&D footprint
Exelixis nabs Merck veteran as chief medical officer on quest to expand its R&D footprint chale Tue, 01/04/2022 - 09:04

